ArticleWorld journal of nephrology2026
Early detection of contrast-associated acute kidney injury after coronary angiography: A predictive value of osteopontin.
Article in World journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-associated acute kidney injury (CA-AKI) is a common and serious complication of percutaneous coronary intervention (PCI). It is linked to higher rates of morbidity and mortality. Early detection of patients at risk is crucial for implementing timely preventive actions. Osteopontin (OPN), a multifunctional glycoprotein highly expressed in kidney tissue, has been suggested as a potential biomarker for AKI. However, its role in CA-AKI remains unclear.
aimTo evaluate the predictive value of serum OPN levels for early identification of CA-AKI in patients undergoing PCI and to compare its diagnostic performance with the Mehran risk score and traditional clinical predictors.
methodsA prospective, non-randomized comparative study was conducted at Assiut University Hospitals between March 2023 and March 2024. A total of 155 patients who underwent elective or primary PCI were enrolled. Exclusion criteria included chronic kidney disease, prior CA-AKI, cardiogenic shock, obstructive uropathy, malignancy, or nephrotoxic drug use. Serum OPN was measured immediately before and after PCI by ELISA alongside routine renal function tests. CA-AKI was defined as ≥ 0.3 mg/dL absolute or ≥ 50% relative rise in serum creatinine within 7 days post-contrast. The primary outcomes were the rate of CA-AKI after PCI and changes in OPN levels. Patients with CA-AKI were compared with patients without CA-AKI. Logistic regression and receiver operating characteristic curve analyses were performed to assess predictors and diagnostic accuracy.
resultsCA-AKI occurred in 20 patients (12.9%). These patients were significantly older (59.54 ± 8.67 years) than those without CA-AKI (48.19 ± 7.89 years;
conclusionElevated OPN levels, both before and after PCI, independently predicted CA-AKI and enhanced the predictive power of the Mehran score. Routine assessment of OPN may provide an effective strategy for early risk stratification in patients undergoing PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.